The demo realized both equally its Main endpoints, with semaglutide 2.4 mg demonstrating statistically sizeable and superior improvements in liver fibrosis with no worsening of steatohepatitis, and resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH compared to place